Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lilly Diabetes R&D Center Arms Firm For Battle In China

This article was originally published in The Pink Sheet Daily

Executive Summary

Lilly’s first R&D center in China will focus on developing therapies that target the genetic profile and dietary habits of Asian diabetes patients.

You may also be interested in...

Lilly’s Lechleiter Sees More Opportunities For Emerging Markets

Eli Lilly CEO John Lechleiter talked about the company’s plans for emerging markets at a recent conference in New York.

Icahn Turns Up The Heat On Amylin, Urges Board To Sell

The activist investor, previously involved in buyouts at ImClone, Biogen Idec and Elan, as well as a proxy fight at Genzyme, scolds Amylin’s board for lack of transparency on purported Bristol offer and asserts the biotech is not positioned to maximize the market potential of Bydureon.

Amylin, Lilly End Exenatide Tie-Up, Marking End To Litigation

Related Content

Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts